At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ACXP Acurx Pharmaceuticals, LLC*
Post-Mkt 09-09 17:43:01 EDT
1.41
-0.02
-1.40%
盘后1.41
+0.000.00%
16:31 EDT
High1.43
Low1.41
Vol32.57K
Open1.41
D1 Closing1.43
Amplitude1.40%
Mkt Cap7.71M
Tradable Cap7.53M
Total Shares5.47M
T/O46.35K
T/O Rate0.61%
Tradable Shares5.34M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Acurx Pharmaceuticals - Files for Resale of 1,500,000 Common Shares - SEC Filing
Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase Iiic Inhibitor Antibiotics
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.